Newsletter
DTx Podcast with Eugene Borukhovich

DTx Podcast with Eugene Borukhovich

Season 2, by Digital Health Today

All Episodes

Treating Disease Progression with DTx: Dr. Mark Berman Shares Insights on Innovative Prescription Digital Therapeutics

Cognitive behavioral therapy (CBT) is an evidence-based form of therapy that has been in use for decades. My guest in this episode believes that CBT can be applied to create better therapeutics, and, in fact, that's exactly what his company is called: Better Therapeutics. Dr. Mark Berman, the Chief Medical Officer at Better Therapeutics, explained that the goal of CBT is to "help people change some of those core beliefs, which then directly influence what we do on a day to day basis." And while CBT was originally applied to help people with conditions like PTSD, anxiety and depression, the team at Better Therapeutics have developed their own variant of CBT to apply the core principles of CBT to the ideas that drive root behaviors like diet, exercise and other supportive lifestyle behaviors. Tune into this episode to hear how Better Therapeutics are creating new digital treatments to reverse the progression of cardiometabolic disease, improve quality of life and inform clinical decisions. In this episode, we cover: Patient experience using digital therapeutics for type 2 diabetes Nutritional CBT - Better Therapeutics innovative new form of Cognitive Behavioral Therapy Why companies are opting to create Prescription Digital Therapies rather than self-managed lifestyle apps What’s next in the Better Therapeutics pipeline and how these decisions are made The future of Digital Therapeutic infrastructure Guest Links and Resources: Connect with Mark Berman on LinkedIn | Twitter Visit bettertx.com Episode Mentions: Kevin Appelbaum - founder of Better TX: LinkedIn Margaret Moore - Founder & CEO Wellcoaches Corporation: LinkedIn Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram
June 30, 2022
Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram " data-cover="https://megaphone.imgix.net/podcasts/39ad28a6-dd06-11ec-b010-4fdc1a9c020d/image/dht-dtx-1400___1400_px.jpg?ixlib=rails-2.1.2&max-w=3000&max-h=3000&fit=crop&auto=format,compress">
Play now

DTx Treatment of Nightmare Disorder with the Apple Watch

Everyone knows it's important to get a good night's sleep, but what if nightmares are keeping you aware? Frequent nightmares can disrupt your sleep, cause stress and interfere with your ability to function during the day. A diagnosis of "nightmare disorder" can occur if disturbing dreams cause stress and keep someone from getting enough sleep.(1) This episode features Grady Hannah, co-founder and CEO of NightWare, the company behind an innovative prescription digital therapeutic that alleviates the effects of traumatic nightmares most often associated with PTSD. Through software on an Apple Watch, NightWare monitors a persons' sleep patterns, and uses machine learning to identify a patients' nightmares and intervene in them. Once a nightmare is detected, NightWare can activate the watch to wake the sleeper out of traumatic nightmares, but without actually waking them out of sleep. In this episode, we cover: The problem and solution that led to developing a DTx for Apple Watch The types of trauma that can lead to Nightmare Disorder or nightmares from PTSD Evidence generation required to support FDA "Breakthrough Status" in 2020 How to reach out and educate prescribers Guest Links and Resources: Connect with Grady Hannah on LinkedIn Visit NightWare on the Web Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram (1) Mayo Clinic: https://www.mayoclinic.org/diseases-conditions/nightmare-disorder/diagnosis-treatment/drc-20353520
June 23, 2022
Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram (1) Mayo Clinic: https://www.mayoclinic.org/diseases-conditions/nightmare-disorder/diagnosis-treatment/drc-20353520 " data-cover="https://megaphone.imgix.net/podcasts/39919a46-dd06-11ec-b010-9f1b71cb4523/image/ca-grady-hannah.jpeg?ixlib=rails-2.1.2&max-w=3000&max-h=3000&fit=crop&auto=format,compress">
Play now

Can Music be Used as Medicine? MedRhythms' Digital Therapeutic Measures and Improves Gait and Ability to Walk

The association between music and medicine has been discussed for decades, and the development of music therapy has been shown to improve outcomes for patients of all ages, and from the immune system to the mind. To tell us more about how music can play a role in digital therapeutics, we hear from Brian Harris, the Co-founder and CEO of MedRhythms. MedRhythms is a digital therapeutics company focused on the intersection music, neuroscience and technology. They understand that millions of people live with persistent walking deficits due to injury or disease, and, to address the needs of this patient population, MedRhythms is building the world's first prescription music platform. Thanks to MedRhythms partnership with Universal Music Group, they provide patients with therapy via music that they know and enjoy. This enables their digital therapeutics to use music content that is curated and screened via a patented process, which carefully selects and customizes interventions to each user. Tune in for an interesting discussion that will make you want to sit up and hear the music! Topics covered: The genesis of MedRythms - why it all started and going from hospital to home. How music can be used to improve walking following neurologic disease and injury  Evidence generation and how it is evolving Why MedRhythms decided to go the route of a PDT (Prescription Digital Therapeutic) rather than a consumer route Let's talk DTx business: what was the MedRythms original business hypothesis, and how did it change over time? Can you talk about pricing at all?  If you were to dissect your deal with Biogen, what is your business hypothesis on how this partnership will make you both money ? MedRhythms partnership with Universal Music Group, and what it means to users and much more! Guest Links and Resources: Connect with Brian Harris on LinkedIn | Twitter Visit MedRhythms, Inc. Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram
June 16, 2022
Play now

The Evolving Regulatory Path for DTx: Jason Brooke Shares Insights on 510(k), De Novo, PMA and International Classification Processes for DTx

Join me for this conversation with M. Jason Brooke, MSE, JD, CSQE, Attorney and Managing Member of Brooke Consulting LLC. Brooke Consulting is a digital health legal and regulatory advisory firm. Jason offers a unique, multi-disciplinary perspective on the digital health industry as a regulatory attorney, scientist, technologist, and quality consultant. Jason and I talk about the three main pathways through the FDA: the 510(k) process, De Novo process and PMA (Premarket approval) process. We discuss the pros and cons of each pathway, and the requirements for testing and clinical data. Jason also explains the types of different types of testing such as verification and validation (bench top) testing, non-clinical animal testing, and clinical testing. But what about cybersecurity and biocompatibility which may be required for some SaMD (Software as a Medical Device) and sensors used in DTx solutions? Yes, Jason shares some insights on that as well! In this episode, we cover: Key milestones over the past 10 years for the DTx industry from a regulatory perspective Pros and cons of pursuing one of the three main pathways for FDA approval for a DTx Jason's opinion about what is currently missing with DTx SaMD regulation to uphold it to the same standard as a medical device Comparisons of the regulatory developments in the US to other areas of the world (EU, APAC) The future of regulatory frameworks for DTx Predictions and suggestions for regulators as the DTx industry moves forward Guest Links and Resources: Connect with Jason Brooke on LinkedIn FDA Information about Sofware as a Medical Device (SaMD) Visit Brooke Consulting's website About Jason: Jason Brooke brings a focused expertise in the medical device industry that combines nearly 20 years of experience ranging from science and technology design, development, implementation, and testing; to business strategy and operations; to legal and regulatory compliance. Jason has conducted scientific research (pre-clinical and clinical) and technology development in academic and industry environments as a biomedical engineer, worked within the FDA’s Center for Devices and Radiological Health as a regulatory affairs program analyst, counseled clients as an attorney and consultant focused on the medical device and digital health space, and served as the chief executive officer, general counsel, and vice-president of regulatory and quality for small medical device companies.  Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram
June 9, 2022
Play now

The Winding Commercial Path for DTx: Mike Pace Shares the Work Done on Commercialisation Models & Where We Go Next

In this episode, we hear from Mike Pace, Founder & CEO of PalmHealthco. PalmHealthco provides market access, commercialization, evidence generation and go-to-market executive advisory and strategic consulting services to digital health, biopharmaceutical and medical device firms around the world.  Mike and I talk about the differences in going to market and the commercial pathways for biopharmaceuticals compared to PDTs. Mike talks about what we are seeing in the marketplace with some of the early PDT trailblazers and the opportunity within the industry that exists for patient centric and value-based care. We discuss the conundrum of pricing PDTs, what other countries are leading the way in the industry… and more! In this episode, we cover: The work and progress we've seen in the marketplace with some of the early trailblazers and leaders Should the DTx industry continue to pursue claims-based reimbursement, or would it be better to jump straight to value-based reimbursement? What is the incremental benefit a digital therapeutic product gains in payment or reimbursement dollars by just labeling itself as a digital therapeutic versus not doing so? How do we build the adoption flywheel for DTx and not have price become an obstacle? Guest Links and Resources: Connect with Mike Pace on LinkedIn | Twitter Learn more about PalmHealthCo Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram
June 2, 2022
Play now

Pharmacy Meets DTx: Tim Aungst Shares How Pharmacy Services Can Support Digital Therapeutics

In this episode, we hear from Timothy Aungst, a clinician, academic, public speaker, writer and, of course, pharmacist. In 2016, Tim founded The Digital Apothecary as a blog specifically for pharmacists to provide news and resources related to digital health topics and interests. Tim is also an advisor at HealthXL, a Clinical Writer for GoodRx, a member of the Digital Therapeutics Alliance Healthcare Provider Advisory Group, and an Associate Professor of Pharmacy Practice at Massachusetts College of Pharmacy and Health Sciences. In this episode, we cover: The role of the Pharmacist as it relates to DTx How do we compare Prescription Digital Therapeutics (PDT) versus traditional standards of care? How are DTx dispensed? And how do pharmacists at the front lines feel about DTx? Do pharmacy services need to be redesigned in the context of DTx? Do DTx have drug interactions? How do we train current and future learners about DTx and the digitization of healthcare? Guest Links and Resources: Connect with Timothy Aungst, PharmD on LinkedIn | Twitter Visit The Digital Apothecary Episode Mentions: Megan Coder Risa Vatanka APhA - Annual Meeting and DigitalHealth.Rx Digital Therapeutics Alliance Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram
May 26, 2022
Play now

Digital Therapeutics Alliance (DTA): The Next Chapter in Scaling the DTx Industry

In this episode, we hear from Andy Molnar, CEO at the Digital Therapeutics Alliance. Andy dives into what they are working on to propel the DTx industry forward, and the international scope of his work in Europe, Asia Pacific and beyond. We also discuss the recent trends with commercial payers and reimbursements - or lack thereof - and much more. Key Takeaway: Be sure to check out the link to the DTx Value Assessment and Integration Guide put together by the DTx Alliance. It is designed to support healthcare decision makers as they assess and integrate DTx products into clinical use settings.  Guest Links and Resources: Learn more about Digital Therapeutics Alliance | Twitter | LinkedIn Connect with Andy Molnar Download the DTx Value Assessment & Integration Guide Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram
May 19, 2022
Play now

DTx Rewind and Where We Go From Here

We’ve got a very special guest on this episode. In Season 2 of DTx Podcast, we will focus greater attention on the evidence and commercialization of Digital Therapeutics. To bring even more context and insights to these conversations, I'm excited to introduce my partner this season: Dr. Chandana Fitzgerald, or as you’ll hear her own name of choice - "Dr No Craic"! Don't worry, the name will be explained in this episode. Join us as we briefly rewind the past year in DTx as we discuss SPAC’s and going public, new entrants and exits in the DTx space, and much more. Chandana also asks me a few questions about the history and goal of the DTx Podcast and what we have to look forward to in season two. But before we dive in… I remember when Martin Kelly introduced me to Chandana at one of the HealthXL events about 5 years ago. Chandana was witty, sharp and fun to speak with. Chandana comes from a clinical background as a physician, and is now the Chief Medical Officer and General Manager of HealthXL. And, as you'll here in this first episode of Season 2 of DTx Podcast, she's also my clinical and commercialization partner with all the tough questions for our guests!  Links and Resources: Brian Dolan Martin Kelly Ed Cox Dan Kendall Better Therapeutics Pear Therapeutics Akili Interactive Pierre Leurent Cognito Therapeutics Digital Therapeutics Alliance Mark Sluijs Alex Therapeutics Karuna Labs Nightware Smiley Scope Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram
May 12, 2022
Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram " data-cover="https://megaphone.imgix.net/podcasts/15ef2c14-d141-11ec-9013-13a426ab04e3/image/ca-s2ep1-DTx-Chandana-Fitzgerald-MD.png?ixlib=rails-2.1.2&max-w=3000&max-h=3000&fit=crop&auto=format,compress">
Play now

Introducing Season 2 of Digital Therapeutics Podcast!!

In this episode, we officially announce that the Digital Therapeutics Podcast is back for Season 2!  And the good news keeps coming as Eugene Borukhovich resumes his role as the talented host of the series! Eugene is a serial intra- and entrepreneur, executive, venture builder, speaker & board advisor with a focus in digital health. He’s also the COO and co-founder at YourCoach.Health, the leading health coaching ecosystem working to deliver the power of health coaching to the world’s population.  Eugene is using his voice to make some noise about the exciting things happening in healthcare and specifically in Digital Therapeutics. Tune in as we share the success to date, what caused him to resume his hosting duties, and what's in store for Season 2! Links: Season 1, Episode 13 with Chris Bergstrom April Fool's Post: A DTx to Overcome Podcast Hesitancy Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health
May 4, 2022
Play now

Ep23: Conclusion: Reflecting on DTx Limited Edition Series

In this final episode of Digital Therapeutics Edition, Eugene and his journalistic partner, Brian Dolan, reflect on the lessons learned, guest experts, and inspiring stories featured in season one. Brian is a journalist and the founder and lead writer of Exits & Outcomes, and in each episode, he asked the guests a pointed and challenging question about their digital solutions or their outlook on the DTx industry.  It's been an eventful five months, Brian says -- companies have been bought, merged, and sold, and have raised impressive rounds of funding -- but there are other areas that have seen little progress since the podcast was launched. There may be a season 2 of Digital Therapeutics Edition, but in the meantime, head over to healthxl.com/dtx to continue the conversation with Eugene and other experts. What do you think the future of DTx will look like?  >>Click here to read the transcript Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
June 1, 2021
Play now

Ep22: Clinically-Validated DTx Solutions for Unmet Needs

Abhishek Shah, the CEO and founder of Wellthy Therapeutics, is driven by the challenge of improving care delivery and outcomes for serious or chronic diseases like hypertension, type 2 diabetes, and kidney disease. Abhishek decided to start Wellthy after a successful career as an investor; he was inspired by the incredible ideas of other entrepreneurs, and tired of sitting on the sidelines, decided to build something himself.  Eugene and Abhishek talked back in December, and in that time, Wellthy has laid the groundwork for expansion throughout Asia Pacific and Europe. Eugene and Abhishek talk about his efforts to get investors to back Wellthy, the technology and regulatory landscape for DTx in South Asia, and whether Wellthy is facing competition from other industry players like Apollo during the COVID-19 pandemic. >>Click here to read the transcript Guest Links and Resources: Connect with Abhishek Shah: LinkedIn | Twitter Visit Wellthy Therapeutics: Twitter | LinkedIn | Facebook | Instagram | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
May 25, 2021
Play now

Ep21: Investing in Prescription DTx

Edward Kliphuis says his love for investing in digital health comes from his love of "playing with toys" and imagining the possible benefit to health outcomes if "damn cool" solutions are scaled significantly.  M Ventures backs many impressive companies-- like BioLink, Sonde Health, and Akili. In this episode, Ed talks to Eugene about M Ventures' founding philosophy (how to cut delayed feedback cycles, which M Ventures views as the biggest threat to humanity), approach to investing, and discusses some of the drivers of capital injections in the DTx space. Also, Ed offers his insight into what makes for a truly successful DTx company. >>Click here to read the transcript Guest Links and Resources: Connect with Edward Kliphuis: LinkedIn Visit Amadeus Capital Partners: Twitter | LinkedIn | Website Visit M Ventures: LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
May 18, 2021
>Click here to read the transcript Guest Links and Resources: Connect with Edward Kliphuis: LinkedIn Visit Amadeus Capital Partners: Twitter | LinkedIn | Website Visit M Ventures: LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche " data-cover="https://megaphone.imgix.net/podcasts/290fd35e-b73c-11eb-b0de-273dfed6130d/image/dht-dtx-edward-kliphuis-1080x1080.png?ixlib=rails-2.1.2&max-w=3000&max-h=3000&fit=crop&auto=format,compress">
Play now

Ep20: Investing in DTx Businesses

Will Gibbs came to Octopus Ventures via a circuitous route - which interestingly, included setting up a rare breed pig farm in his native Essex. He landed in venture capital because he loves to build things - especially large-scale solutions for "taboo" or overlooked medical conditions like substance addiction, menopause, and acne.  Will and Eugene peek underneath the hood of venture capital. They discuss Octopus Ventures' investments in companies like Big Health and Quit Genius, the ins and outs of investing in DTx solutions, whether there is a valuation bubble in the DTx space, and Will offers some advice for startups looking to raise funds. >>Click here to read the transcript Viewing in Apple Podcasts? Visit our website for links to everything below: https://digitalhealthtoday.com/dtx/ Guest Links and Resources: Connect with Will Gibbs: LinkedIn https://linkedin.com/in/willgibbs1/ Visit Octopus Ventures: Twitter | LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
May 11, 2021
>Click here to read the transcript Viewing in Apple Podcasts? Visit our website for links to everything below: https://digitalhealthtoday.com/dtx/ Guest Links and Resources: Connect with Will Gibbs: LinkedIn https://linkedin.com/in/willgibbs1/ Visit Octopus Ventures: Twitter | LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche " data-cover="https://megaphone.imgix.net/podcasts/9d4a585a-b176-11eb-bbb2-1f397556c50e/image/dht-dtx-Will-Gibbs.png?ixlib=rails-2.1.2&max-w=3000&max-h=3000&fit=crop&auto=format,compress">
Play now

Ep19: Digital Therapy for Parkinson’s and Neurological Conditions

Ciara Clancy remembers the exact moment she decided to found Beats Medical; it was when she realized her Parkinson’s patient was 20 minutes late for metronome therapy because he was frozen at the door of the hospital, unable to take a single step. The metronome therapy, which helps Parkinson’s patients with their walking and movement, was only available in hospitals and via prescription. So Ciara decided to bring the therapy to them. Beats Medical turns a Parkinson’s patient’s phone into a medical device that gives live, visual feedback to help improve fine motor and gross motor skills, speech, and psychological well-being. Beats’ core technology has also been repurposed and deployed for other central nervous system (CNS) disorders and to help children cope with stress during the COVID-19 pandemic. Eugene and Ciara talk about some exciting recent developments in Beats’ product line, the evolution of their B2C and B2B models, and how Beats’ users have consistently driven the company to create better and more effective interventions. >>Click here to read the transcript Guest Links and Resources: Connect with Ciara Clancy: LinkedIn | Twitter Visit Beats Medical Ltd: Twitter | LinkedIn | YouTube| Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
May 4, 2021
Play now

Ep18: Improving Outcomes for IBS and IBD Sufferers Through Light Touch Digital Therapy

As a former IBS sufferer, Elena Mustatea knows all too well that our standard model of healthcare does not adequately treat or support people with chronic conditions—especially digestive conditions. Elena eventually took matters into her own hands and attended a detox retreat in Thailand, which restored her physical and mental well-being and gave her the idea to start Bold Health. Bold Health is clinically validated and science-backed, and relieves the painful, life-disrupting symptoms of chronic digestive conditions through cognitive behavioral therapy and relaxation exercises. This intervention is crucial, because as Elena points out, 75% of the population suffers from GI symptoms in any given week, and 30% of the population has a diagnosable, long-term digestive condition. Digestive and autoimmune conditions are an enormous mental health burden and disproportionately affect women. Eugene and Elena talk about Elena’s journey from consulting and venture capital to digital therapeutics, Bold Health’s recent RCT results, and Elena’s view on how digital therapeutics and pharma could work together in the future. >>Click here to read the transcript Guest Links and Resources: Connect with Elena Mustatea: LinkedIn | Twitter Visit Bold Health: Twitter | LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
April 27, 2021
Play now

Ep17: Treating Chronic Pain with DTx

Jonas Duss came to digital therapeutics from a mechanical and chemical engineering background. He landed at Kaia Health after he and his business partner, David Boutellier, realized they all shared a similar mission; to make proven, effective therapies for debilitating chronic conditions more widely accessible through digital platforms. Kaia Health offers people with musculoskeletal conditions virtual physical therapy sessions, complete with a health coach who helps motivate users to stay on track. In this episode, Jonas tells Eugene about Kaia’s founding, the company’s early decision to expand to the US (despite the different regulatory and payment environment), and his driving motivation to help chronic pain sufferers live longer, higher-quality lives. Also, Jonas mentions a McKinsey report on reimbursement in Germany, in which Kaia’s journey is offered as a brief case study. You can find that report here. >>Click here to read the transcript Guest Links and Resources: Connect with Jonas Duss: LinkedIn | Twitter Visit Kaia Health: Twitter | LinkedIn | Instagram | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
April 20, 2021
Play now

Ep16: The Mind(s) Behind Germany’s Digital Health Care Act

During his conscripted service with the German Navy, Christian Dierks learned that if you’re the person in charge of rules and administration, you can bring about a lot of change. He took this lesson with him to law school and in the creation of his own law and healthcare consultancy firm, Dierks+Company. Christian was instrumental in the creation of Germany’s 2019 Digital Health Care Act (known as DVG in Germany), which mandates full reimbursement of any prescribed digital health application. In fact, Christian was involved in setting up the legal framework for digital health applications (DiGA) in Germany—and importantly, he convinced health insurers in Germany not to nickname them DiVA, an acronym which would have carried distinctly less gravitas. Starting with this episode, Eugene says farewell (for now) to DTx trailblazers in the United States, and shifts the focus to leaders in Europe, where Christian and other thought leaders are working to broaden access to digital health solutions. Eugene and Christian recorded this episode in January, and since then, there have been some exciting updates to the status of DVG. Namely, the list of approved digital therapies for reimbursement has grown to 13, and Germany is starting to publish early data on the impact of the measure. >>Click here to read the transcript Guest Links and Resources: Connect with Christian Dierks: LinkedIn | Twitter Visit Dierks+Company: LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
April 13, 2021
Play now

Ep15: Treating Depression, Anxiety, and Sleep Disorders with Happify

Chris Wasden came to the digital therapeutics space via a circuitous route through Wall Street, Main Street, and academia. A pro at finding ways to leverage digital solutions in the pharmaceutical industry, he was asked to lead HappifyDTx’s digital therapeutics business after he and his students identified it as the best digital health company in the world. Happify just closed an impressive $73 million funding round and continues to innovate clinically validated tools to treat depression, anxiety, and sleep disorders. In this episode, Chris tells Eugene how Happify’s founders moved from creating video games to digital health tools, and why the team took on the mammoth effort of creating an FDA-quality management system for its platform of products. As a result of their hard work, Chris says Happify is the only DTx company out there that has a legitimate, placebo-controlled RCT. >>Click here to read the transcript Guest Links and Resources: Connect with Chris Wasden: LinkedIn | Twitter Visit Happify Health: Twitter| LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
April 6, 2021
Play now

Ep14: Building the Genentech of Digital Therapeutics

Corey McCann says he always wanted to name a company after a fruit, and when he and his team saw an opportunity to “pair” drugs and software to treat serious disease and improve patient outcomes, the name Pear Therapeutics was born. Of course, the other inspiration for the creation of Pear Therapeutics was Genentech, in that Corey and his team wanted to build something big and capitalize on the hundreds of opportunities they see to modify standards of efficacy with software solutions. Corey, Eugene, and Brian talk about Pear’s early foray into the digital therapeutics space and how Pear’s digital therapies incorporate doctors, nurses, health coaches, and other human counselors. Also, for any entrepreneurs looking to start their own venture, Corey has several pearls of wisdom for you—one of which is to choose your investors and board members very wisely. Finally, Corey offers his predictions about the future of prescription digital therapeutics and the policy solutions needed to make PDTs viable for all patients. >>Click here to read the transcript Guest Links and Resources: Connect with Corey McCann: LinkedIn | Twitter Visit Pear Therapeutics: Twitter| LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
March 30, 2021
Play now

Ep13: The New Breed of DTx May Not Be a DTx At All

Ask Chris Bergstrom what gets him out of bed in the morning, and he says very simply: “scale, scale, scale.” Chris brings a powerful blend of experience in start-ups, large companies, and the life sciences to his role as president of Amalgam Rx, a digital platform that brings providers and life sciences companies together to grow digital health solutions. Chris and Eugene talk about Amalgam’s origins and capabilities, and in response to a question from Brian Dolan about Amalgam’s recent acquisition of Avhana Health, Chris reveals that Amalgam has been lucky enough to start off as a fully self-funded venture. Finally, listen in as Chris and Eugene discuss whether the term “digital therapeutic” has become passé. >>Click here to read the transcript Guest Links and Resources: Connect with Chris Bergstrom: LinkedIn Visit Amalgam Rx: LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
March 23, 2021
Play now

Ep12: Improving Symptoms of Autoimmune Disorders with DTx Solutions

As an engineer, Melinda Decker could have designed widgets or Styrofoam cups or even gone into winemaking. But her passion for improving patient outcomes led her to digital therapeutics, and eventually to Mymee, a direct-to-consumer platform that helps people with autoimmune disorders manage their symptoms. Mymee recognizes that behavior change is hard, so they combine a user-friendly app and data analytics with health coaching, to help users identify their triggers and make long-lasting lifestyle changes that lessen the severity of their symptoms and improve their overall health. Since its founding in 2017, Mymee has collaborated on two publications and recently closed a funding round of $8.7 million. Join Eugene and Melinda’s conversation about digital therapeutics vs. disease management and the path the Mymee team took to getting their solution off the ground. >>Click here to read the transcript Guest Links and Resources: Connect with Melinda Decker: LinkedIn Visit Mymee: Twitter | LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
March 16, 2021
Play now

Ep11: How Sleepio Digitize's Cognitive Behavioral Therapy to Help Millions Back to Good Mental Health

When Peter Hames struggled with insomnia, he couldn’t get access to any treatment other than sleeping pills. Out of “desperation,” he said, Peter self-administered a cognitive behavioral therapy (CBT) course and within weeks was sleeping like a baby. That experience led to the development of Sleepio, an app which uses artificial intelligence to deliver digital cognitive behavioral therapy to improve user's sleep. I Peter applied his background in experimental psychology and technology to co-found Big Health, a digital therapeutics (DTx) company whose mission is to “help millions back to good mental health.” With 53 peer-reviewed papers and 13 randomized control trials, Big Health is also one of the only DTx companies in the world with an evidence base of its size, rigor, and quality. Join Eugene and Peter as they talk about the early days of digital therapeutics, Big Health’s unique direct-to-consumer approach in the UK and the US, and its deep-rooted commitment to clinical evidence and supporting science. May 20, 2022 News Update: National Institute for Health and Care Excellence recommends the use of Sleepio for treatment of insomnia when compared to pills or other methods Read more on the Telegraph: Trouble sleeping? Doctors will prescribe an app now instead of pills >>Click here to read the transcript Guest Links and Resources: Connect with Peter Hames: LinkedIn Visit Big Health: Twitter | LinkedIn | Website Learn more about Sleepio Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
March 9, 2021
Play now

Ep10: Leveraging Novel Technologies to Meet Unmet Medical Needs – Brent Vaughan CEO, Cognito Therapeutics

There are two kinds of people in the world, says Brent Vaughan — those who prefer to make incremental changes with a lower likelihood of failure, and those who aspire to fix (seemingly) intractable problems that have stymied others. Brent falls in the latter category. A serial entrepreneur, former venture capitalist, and current CEO of Cognito Therapeutics (a DTx company that specializes in neurodegenerative diseases), Brent is also uniquely positioned to evaluate the future of next generation digital therapeutics. Brent and Eugene talk about the differences between prescription and business-to-consumer DTx, the importance of engaging patients and users early on in the development of novel products, and the exciting potential of translational DTx solutions. Eugene’s podcast partner, Brian Dolan, also pops in with a question. >>Click here to read the transcript Guest Links and Resources: Connect with Brent Vaughan: LinkedIn Visit Cognito Therapeutics: Twitter | LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
March 2, 2021
Play now

Ep09: Lessons From the Trenches: Ed Cox shares his experiences at Dthera and building a DTx for Alzheimer's

In this episode, I speak with Ed Cox, who is an Executive Vice President of Strategic Alliances and Global Head of Digital Medicines at EVERSANA. In our conversation, we focus on his journey through Dthera and the many lessons learned.  But before we dive in: Those of you who know Ed, will agree, he is a memorable guy, and therefore I am super surprised I can not even remember where we first met but what I do know is that every time I speak with Ed, I feel like I have known him my whole life.   >>Click here to read the transcript Be sure to check out my previous episode where I spoke with David Klein, CEO and Founder of Click Therapeutics - a company that was started in 2012 as a smoking cessation app and now with a pipeline of DTx therapies and a $500M deal with Boehringer Ingelheim.  Guest Links and Resources: Connect with Edward Cox: LinkedIn Visit EVERSANA : Twitter | LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
February 23, 2021
Play now

Ep08: Building a DTx Company as a Biotech – Click Therapeutics with David Klein

In the last episode, I had the pleasure of speaking with Eddie Martucci, CEO and Founder of Akili Interactive - the creators of EndeavourRx, which is the first and only prescription treatment delivered through a video game. Imagine that! In this episode, I continue my DTx journey with yet another early trailblazer, David Klein, CEO and co-founder of Click Therapeutics. I first met David at Frontiers Health conference a few years back. He struck me as cool and composed, with a clear vision. Tune in as David shares a little bit of his background and how did he come to starting Click Therapeutics back in the day. >>Click here to read the transcript Guest Links and Resources: Connect with David Klein: LinkedIn Visit Click Therapeutics: Twitter | LinkedIn | Facebook | Instagram | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
February 16, 2021
Play now

Ep07: Akili's Revolutionary Digital Therapeutic with Eddie Martucci Co-Founder/CEO of Akili

On the last episode, I got to know Anand Iyer, Chief Strategy Officer at WellDoc, who was instrumental in getting the Digital Therapeutics Alliance up and running. In this episode, the focus on the early trailblazers of the DTx industry continues with Eddie Martucci. Eddie is the CEO and founder of Akili Interactive, which has taken a super interesting go to market approach. I very briefly met Eddie, at a small event during the JPMorgan conference in San Francisco years ago. Eddie's energy and passion for the product exuded while he was showing a crowd of onlookers an early version of a game that is now an actual digital therapy, EndeavorRx Click here to read the transcript Guest Links and Resources: Connect with Eddie Martucci: Twitter | LinkedIn Visit Akili Interactive Labs Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
February 9, 2021
Play now

Ep06: The Early Days of Welldoc and DTx with Anand Iyer, Chief Strategy Officer of Welldoc

In this episode, we speak with another one of the early trailblazers of the DTx industry, Anand Iyer, the Chief Strategy Officer of Welldoc. I briefly met Anand at a Health XL event in New York City early in 2019, even though Welldoc has been around since 2008. I'm not even sure how we did not run into each other before, but it was great to connect with Anand for this podcast and get to know him and what drives him, not to mention speak about the early days of Welldoc and DTx industry. Click here to read the transcript Guest Links and Resources: Connect with Anand Iyer: Twitter | LinkedIn Visit Welldoc Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
February 2, 2021
Play now

Ep05: Prescription Digital Therapeutics with Pierre Leurent, CEO of Voluntis

In this episode, we speak with one of the founding members of the Digital Therapeutics Alliance ('DTA'), Pierre Leurent. Pierre is the CEO and founder of Voluntis, which is the first publicly listed DTx company on Euronext in Paris. Pierre co-founded Voluntis in 2001 with the mission to improve patients’ experience with their treatment thanks to digital technologies. Now, 20 years later, they have supported more than 600,000 patients and deployed over 50 programs around the world. Pierre is a Director of the Digital Therapeutics Alliance, of which he served as Chairman, and a member of Advamed’s Digital Health Executive Leadership Group. He previously co-chaired the digital therapeutics task force of the Personal Connected Health Alliance, a member of HIMSS, and chaired the eHealth France Alliance regrouping several leading trade organizations representing digital and life sciences companies in France. Pierre holds a MS from Ecole Centrale Paris. Links and Resources: Connect with Pierre Leurent: Twitter | LinkedIn Visit Voluntis Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
January 26, 2021
Play now

Ep04: Digital Therapeutics Alliance, Deep Dive Part 2 with Jessica Shull, European Lead

In the previous episode in this two-part deep dive inside the Digital Therapeutics Alliance, I spoke to Megan Coder, the Executive Director for the DTA. In this episode, I'm excited to chat with Jessica Shull, European lead for the DTA. I met Jessica and Sitges, Spain near Barcelona at a HIMSS EU Health 2.0 event. Jessica struck me as sharp, composed and super knowledgeable, and of course, a great addition to the DTA. With Jessica's leadership, the DTA expanded its coverage across Europe, LATAM and Australia. Click here to read the transcript Links and Resources: Connect with Jessica Shull: Twitter | LinkedIn Visit the Digital Therapeutics Alliance Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
January 19, 2021
Play now

Ep03: Deep Dive Inside the Digital Therapeutics Alliance with Executive Director Megan Coder

In the previous episode, Brian Dolan and I discussed the definition of digital therapeutics. The term 'digital therapeutics' has been used since about 2012, and in 2017 the Digital Therapeutics Alliance, aka DTA, came on the scene. In this two-part deep dive we go inside the DTA and in this episode, we start with Megan Coder, the Executive Director. I remember meeting the energetic, polished, and absolutely no BS, Megan, at the 2017 Frontiers Health in Berlin - yes, when face-to-face conferences were still a thing. At that conference, the DTA was officially launched. I strongly believe this was a historic moment for the overall industry. Click here to read the transcript Links and Resources: Connect with Megan Coder: Twitter Visit the Digital Therapeutics Alliance Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
January 12, 2021
Play now

Ep02: Start here: What are Digital Therapeutics and How Has the Industry Evolved?

Eugene kicks off the Digital Therapeutics Podcast with journalist and entrepreneur Brian Dolan. Eugene met Brian way back in the pre-iphone days of 'mobile health' (that was before apps, before 4G, before tablets). In this episode, Brian describes how the need for innovation in tech and health led him to create MobiHealthNews. After selling MobiHealthNews to HIMSS in 2015, and is now is the founder and lead writer of Exits and Outcomes. A self-described 'fanboy' of Exits & Outcomes, Eugene invited Brian to be his sparring partner on this limited podcast series. Tune in as they dive into the past, present and future to uncover the truth about Digital Therapeutics. Click here to read the transcript Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
January 5, 2021
Play now

Ep01: Introducing the Host of the New Digital Therapeutics Podcast: Eugene Borukhovich

In this episode, I have the pleasure of introducing you to one of the health sectors leading innovators, and probably one of the best known and, dare I say it, most loved, leaders I’ve had the pleasure of knowing in my 20 plus years working in healthcare: Eugene Borukhovich. He’s a serial intra- and entrepreneur, executive, venture builder, speaker & board advisor with a focus in digital health. He’s also the Chairman and Founding Board Member at YourCoach.Health and founder of Initium Impact Ventures.  Prior to YourCoach, Eugene served as Global Head of Digital Health at Bayer. He has also co-founded and sold a doctor rating startup and a consulting company. Eugene recently relocated to Barcelona where he enjoys running, writing, traveling and spending time with his family. Click here to read the transcript Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche
January 5, 2021
Play now

Trailer: Introducing Digital Therapeutics with Eugene Borukhovich

Join host Eugene Borukhovich as he explores how non-molecular therapies and interventions can prevent, manage or even cure diseases. In this limited series produced with Digital Health Today, learn about the rapidly evolving field of Digital Therapeutics, its history, the evolving regulatory and reimbursement frameworks, and the trailblazers creating and advancing this industry.
November 11, 2020
Play now

About DTx Podcast with Eugene Borukhovich

Learn about the rapidly evolving field of Digital Therapeutics, its history, the evolving regulatory and reimbursement frameworks, and the trailblazers creating and advancing this industry.

Never miss DTx Podcast with Eugene Borukhovich

Join Our Newsletter

Proudly supported by:

cover
What Will Variant Sigma Look Like? with Michael T. Osterholm, Ph.D., Regents Professor, Division of Environmental Health Science; Director, Center for Infectious Disease Research and Policy (CIDRAP) University of Minnesota